Skip to content
You can now search across every topic, entity and event.What's new
UK Startups and Innovation
22APR

IMU raises £40m to read blood

2 min read
17:16UTC

IMU Biosciences closed an oversubscribed £40m Series A on 2 June, co-led by IQ Capital and Molten Ventures, with the British Business Bank co-investing on its second UK life-sciences cap table inside a fortnight.

← Back to Britain's innovation pipe leaks at both endsJump to analysis ↓
TechnologyDeveloping
Key takeaway

State capital is now a routine equity co-investor on British biotech cap tables beside specialist funds.

IMU Biosciences closed an oversubscribed £40m ($53m) Series A on Tuesday 2 June. IQ Capital and Molten Ventures co-led, with the British Business Bank (BBB) co-investing. Oversubscribed means investors sought more shares than the company offered. The platform extracts more than 100 million immune-system data points from a single blood sample, so one routine draw could replace a battery of separate immune tests. 1

The BBB had put £12m into Cytospire's £61m Series A in May and £50m into the Longwall deep-tech fund . Its £6.6bn expanded mandate lets it lead and co-invest directly in startups rather than backing them only through fund intermediaries.

That pattern reframes what UK state capital does at this stage. A development bank acting as a backstop appears when private money is absent; the BBB is appearing precisely where private money is already present, sitting beside IQ Capital and Molten on a priced biotech round. State capital is becoming a recurring line on British biotech cap tables rather than a substitute for the funds it sits beside.

Deep Analysis

In plain English

A standard blood test measures perhaps 20-50 different immune markers at once. IMU Biosciences has built a platform that measures over 100 million data points from a single blood sample, a four-to-five order of magnitude jump in resolution. Immune system data is medically useful because immune patterns appear early in many diseases, sometimes before other symptoms. At this density, IMU can identify correlations that simpler assays miss entirely: which patients will respond to a specific immunotherapy, or which immune signatures predict disease progression. The £40m raised funds the clinical validation studies needed to convert that data density into diagnostic products that hospitals and pharmaceutical companies will pay for.

What could happen next?
  • Precedent

    The BBB's third direct life-sciences co-investment in six weeks (Cytospire, Quantum Motion, IMU) establishes a pattern: UK state capital now participates routinely in private biotech rounds as a minority co-investor alongside specialist VCs.

  • Opportunity

    The 100-million-data-point density creates a pharmaceutical partnership opportunity: drug companies running immunology trials can pay per-assay fees for immune profiling at a resolution unavailable elsewhere.

Sources:UK Tech News
Mentions:IQ Capital →British Business Bank →Cytospire Therapeutics →Longwall Ventures →IMU Biosciences →Molten Ventures →
First Reported In

Update #7 · OQC's £260m sets European quantum record

UK Tech News· 7 Jun 2026
Read original →
Causes and effects
Caused by
Cytospire's £61m oncology Series A oversubscribed
BBB's £12m co-investment in Cytospire's Series A in May established the direct BBB biotech co-investor pattern repeated in IMU Biosciences.
Occurred 5 May 2026
Read story →
State £50m backs the tier funds skip
BBB's £50m Longwall deep-tech fund cornerstone in May is part of the same expanded mandate that brought BBB onto IMU's cap table directly.
Occurred 27 May 2026
Read story →
Jobs plan targets the lab-skills gap
The plan addresses the same staffing gap IMU Biosciences' £40m AI-biotech round in June assumed was solved.
Occurred 9 Jul 2026
Read story →
This Event
IMU raises £40m to read blood
The state bank's repeat direct co-investment shows it acting as a routine equity partner in British biotech, not a lender of last resort.
Led to
Neubond seed is Japan VC's UK first
IMU Biosciences' £40m Series A is part of the UK-research-producing-companies pattern Neubond's Japanese-funded seed continues.
Occurred 15 Jun 2026
Read story →
Alchemab wins Bank's record £25m cheque
IMU Biosciences' £40m June round set the AI-biotech benchmark that Alchemab's £25m cheque extends.
Occurred 9 Jul 2026
Read story →
Different Perspectives
Institute of Physics
Institute of Physics
The Institute has long argued STFC's national-laboratory infrastructure, not its grant programmes, is the binding constraint on UK physics output, and warns mothballing capacity like Clara removes capability that cannot be rebuilt on a four-year cycle. It represents the discovery-science community absorbing the reallocation the Bank's equity cheques do not touch.
Helsing
Helsing
The Munich-headquartered defence-AI firm chose Plymouth over Continental sites for a £350m manufacturing plant building underwater surveillance gliders, alongside its record raise. Its choice of postcode signals confidence in UK manufacturing capacity for defence hardware even as it looks abroad for the capital financing that hardware.
Dragoneer Investment Group, Lightspeed Venture Partners and Iconiq
Dragoneer Investment Group, Lightspeed Venture Partners and Iconiq
The three US growth-capital firms backed Helsing's $1.8bn round at an $18bn valuation, more than doubling the mark set only a year earlier, with demand reportedly exceeding the capital on offer. Their money, not a UK sovereign vehicle, is what funds the Plymouth plant, extending a pattern of foreign capital underwriting British defence-hardware manufacturing this cycle.
British Business Bank
British Business Bank
The Bank wrote its largest-ever direct life-sciences cheque into Alchemab and added a £6.5bn SME lending guarantee the same week UKRI confirmed the STFC cuts. It is deploying an April mandate change letting it lead venture rounds and invest directly up to £60m per company, treating equity extension rounds and small-business debt as newly within its risk appetite.
Daphni
Daphni
The Paris seed fund joined Speedinvest and three UK backers in Astral Systems' GBP23m Series A for modular fusion reactors, one of the round's five European co-investors betting on lab-to-market fusion ahead of any working commercial reactor. Unlike CuspAI's all-foreign cap table, this round kept a UK lead investor in Mercia Ventures.
EQT
EQT
EQT, appointed by the European Innovation Council to run the EUR5bn Scaleup Europe Fund, entered advanced talks for a further CuspAI stake reported on 3 July, the fund's first pursuit of a UK-founded winner. A closed deal would put EU sovereign capital, not a UK vehicle, on the cap table of a company Britain's own funds passed over.